Loading stock data…
Alpha Tau Medical Ltd (DRTS)
$11.22+0.34 (+3.13%)
Market ClosedLast close Jun 29
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alpha Tau Medical Ltd. in the Healthcare sector is trading at $11.22 with a market capitalization of $840M. Wall Street consensus targets $14.20 (5 analysts), implying a +26.6% move over the next 12 months. The stock is currently near its 52-week high of $11.62, remaining 71.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +26.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.31M↓ | -$12.60M↓ | -$10.73M↓ | -$9.65M↓ | -$9.31M |
| Net Income | -$22.94M↓ | -$12.14M↓ | -$11.69M↓ | -$10.11M↓ | -$8.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technolog...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$840.03M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-82.01%
Volume
Today's trading volume
869,860
Recent News
Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform
Alpha Tau Medical recently reported that its Alpha DaRT technology was used to safely treat a recurrent glioblastoma patient in Israel, marking the first intracranial application of its brain-specific delivery system outside the United States at Hadassah University Medical Center. This procedure not only extends Alpha DaRT’s reach into one of the most aggressive adult brain cancers, but also highlights the versatility of its minimally invasive, neuronavigation-guided platform across multiple...
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing
Alpha Tau signed an agreement with Tolmar to commercialize its lead cancer therapy for prostate cancer in the United States.
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s most important trials are “coming to a head” over the coming months. Levy said the company is
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and clinical investigators describing initial tumor responses and safety observations from the pilot trial. Th
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased
Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting what company leadership described as “real and meaningful activity” over the past few months and setting expectations for multiple data readouts later in 2026. The discussion